isofraxidin and Acute-Lung-Injury

isofraxidin has been researched along with Acute-Lung-Injury* in 2 studies

Other Studies

2 other study(ies) available for isofraxidin and Acute-Lung-Injury

ArticleYear
Isofraxidin ameliorated influenza viral inflammation in rodents via inhibiting platelet aggregation.
    International immunopharmacology, 2020, Volume: 84

    Platelets have been proved to exacerbate influenza infection and its complications. Inhibition of platelet activation may be a feasible method for preventing severe infection and secondary acute lung injury (ALI). Isofraxidin (IFD) is a natural coumarin isolated from the plants Sarcandra glabra and Siberian ginseng, and exerts anticancer, antioxidant and antiinflammatory effects. In the present study, we examined the therapeutic effects of IFD in ADP- or arachidonic acid (AA)-induced platelet aggregation model and in influenza A virus (IAV)-induced ALI mouse model. The results showed that IFD significantly inhibited platelet aggregation induced by ADP and AA in vitro in a concentration-dependent manner as well as the release of soluble P-selectin and platelet factor 4. Moreover, IFD significantly relieved IAV-induced lung inflammation, reduced the expressions of platelet activation biomarkers (P-selectin and CD61), decreased the serum levels of TNF-α, IL-1β, IL-6 and MIP-2, suppressed peripheral platelet aggregation and prolonged the survival time of infected mice. The western blotting results also demonstrated that IFD reduced the phosphorylation levels of PI3K, AKT and p38 in the activated platelets stimulated by ADP and IAV infection. But IFD did not have any effects on IAV replication. It indicated that IFD ameliorated IAV-induced severe lung damage and lethal infection by suppressing platelet aggregation via regulating PI3K/AKT and MAPK pathways.

    Topics: Acute Lung Injury; Alphainfluenzavirus; Animals; Anti-Inflammatory Agents; Coumarins; Cytokines; Dogs; Inflammation; Madin Darby Canine Kidney Cells; Male; Mice, Inbred ICR; Mitogen-Activated Protein Kinases; Orthomyxoviridae Infections; Phosphatidylinositol 3-Kinases; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley

2020
Protective effects of Isofraxidin against lipopolysaccharide-induced acute lung injury in mice.
    International immunopharmacology, 2015, Volume: 24, Issue:2

    Acute lung injury (ALI) is a life-threatening disease characterized by serious lung inflammation and increased capillary permeability, which presents a high mortality worldwide. Isofraxidin (IF), a Coumarin compound isolated from the natural medicinal plants such as Sarcandra glabra and Acanthopanax senticosus, has been reported to have definite anti-bacterial, anti-oxidant, and anti-inflammatory activities. However, the effects of IF against lipopolysaccharide-induced ALI have not been clarified. The aim of the present study is to explore the protective effects and potential mechanism of IF against LPS-induced ALI in mice. In this study, We found that pretreatment with IF significantly lowered LPS-induced mortality and lung wet-to-dry weight (W/D) ratio and reduced the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in serum and bronchoalveolar lavage fluid (BALF). We also found that total cells, neutrophils and macrophages in BALF, MPO activity in lung tissues were markedly decreased. Besides, IF obviously inhibited lung histopathological changes and cyclooxygenase-2 (COX-2) protein expression. These results suggest that IF has a protective effect against LPS-induced ALI, and the protective effect of IF seems to result from the inhibition of COX-2 protein expression in the lung, which regulates the production of PGE2.

    Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Cell Count; Coumarins; Cyclooxygenase 2; Dinoprostone; Interleukin-6; Lipopolysaccharides; Lung; Male; Mice; Protective Agents; Tumor Necrosis Factor-alpha

2015